A provision in Florida's H5301 health care bill creates a Medicaid preferred product list that could require prior authorization for suppliers not on it—and most business owners haven't heard about it
Most professional services owners in Florida don't realize that a provision buried deep in H5301—the state's health care bill—could directly restrict which medical suppliers Medicaid providers can use and how quickly they get paid.
Here's what's happening: Starting July 1, 2026, Florida will create a Medicaid preferred product list for therapeutic supplies. Sounds routine. But the real impact is in what comes next.
If your company supplies therapeutic products to Medicaid providers and your products aren't on that preferred list, you'll face a new requirement: prior authorization before Medicaid will reimburse the claim. That's not a minor paperwork step—it's a gatekeeping mechanism that slows payment, creates administrative burden, and can effectively lock smaller suppliers out of the market.
For context: prior authorization delays reimbursement, requires staff time to navigate the approval process, and gives the state control over which products actually reach patients. Suppliers not on the list face friction that listed suppliers don't.
This provision directly impacts:
If you're not on the preferred list, your competitive position weakens immediately. Providers may avoid your products simply to skip the prior authorization step.
There's another concern buried in the language: the agency can update the preferred product list without going through formal rulemaking. That means no public notice-and-comment period. No formal opportunity to petition for inclusion. The list can change, and suppliers may not know until reimbursement gets denied.
For businesses that depend on predictable Medicaid revenue, this creates real uncertainty about market access and cash flow planning.
Effective date: July 1, 2026. You have time to prepare, but not indefinitely.
Legal reference: Section 15 of H5301, which adds subsection 14 to Florida Statute 409.912 (Page 75 of the bill).
Next steps: If you supply therapeutic products to Medicaid providers, now is the time to understand how your product portfolio might be affected. Monitor announcements from the Florida Agency for Health Care Administration about the preferred product list criteria and timeline. Consider whether you'll need to pursue preferred-list status or adjust your business model.
This isn't a crisis—yet. But it is a structural change to how Medicaid reimbursement works in Florida, and suppliers who understand it early will have better options than those who don't.
Source: H5301, Section 15 (subsection 14 added to s. 409.912), effective July 1, 2026.